Files and links (1)
Published VersionCC BY V4.0, Open Access
Journal article
Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model
Vaccines, Vol.13(6), pp.1-28
2025
Abstract
Background/Objectives: Breast cancer remains a leading cause of cancer-related mortality among women worldwide, necessitating novel therapeutic strategies. This study aimed to investigate the synergistic antitumor effects of caerin peptides (F1/F3) combined with dendritic cell (DC) vaccines in a 4T-1 murine breast cancer model, providing new insights for breast cancer immunotherapy.
Methods: In vitro experiments evaluated the effects of F1/F3 on 4T-1 cell proliferation and apoptosis. A 4T-1 breast cancer mouse model was established, and treatments included F1/F3 alone, DC vaccines (DCV1: loaded with whole tumor antigens; DCV2: loaded with F1/F3-induced apoptotic antigens), or combination therapy. Flow cytometry analyzed immune cell subsets in the tumor microenvironment and lymph nodes, while ELISA measured cytokine levels.
Results: F1/F3 significantly inhibited 4T-1 cell proliferation and induced apoptosis while suppressing tumor growth and lung metastasis in vivo. Flow cytometry revealed increased infiltration of CD4+ T cells and cDC1 in tumors, along with reduced PD-L1 expression. DCV2 exhibited stronger T-cell proliferation induction and lower IL-10 secretion in vitro. Combination therapy with DCV2 and F1/F3 demonstrated superior tumor suppression compared to monotherapy.
Conclusions: F1/F3 enhances antitumor immunity by modulating the tumor microenvironment, and its combination with DCV2 yields synergistic effects. This study provides experimental evidence for combination immunotherapy in breast cancer, with potential for further optimization of DC vaccine design to improve efficacy.
Details
- Title
- Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model
- Authors
- Rongmi Mo (Author) - Guangdong Pharmaceutical UniversityJunjie Li (Author) - Zhong′ao Biomedical Technology (Guangdong) Co. Ltd. (China)Xinyi Song (Author) - Guangdong Pharmaceutical UniversityJiawei Fu (Author) - Guangdong Pharmaceutical UniversityMengqi Liu (Author) - Guizhou UniversityYuandong Luo (Author) - Zhongao Biomedical Technology (China)Quanlan Fu (Author) - Zhongao Biomedical Technology (China)Jinyi Wu (Author) - Guangdong Pharmaceutical UniversityYongxin Liang (Author) - First People's Hospital of FoshanHongyin Wu (Author) - First Affiliated Hospital of Guangdong Pharmaceutical UniversityTianfang Wang (Author) - University of the Sunshine Coast, Queensland, School of Science, Technology and EngineeringXiaosong Liu (Author) - Zhongao Bio-pharmaceutical Technology Co., Ltd. (China)Guoying Ni (Corresponding Author) - Zhongao Bio-pharmaceutical Technology Co., Ltd. (China)
- Publication details
- Vaccines, Vol.13(6), pp.1-28
- Publisher
- MDPI AG
- Date published
- 2025
- DOI
- 10.3390/vaccines13060577
- ISSN
- 2076-393X
- Copyright note
- © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
- Data Availability
- The original contributions presented in this study are included in this article/Supplementary Materials. Further inquiries can be directed to the corresponding author.
- Grant note
- First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Science and Technology Department (2016A020213001) National Science Foundation of China (31971355) The Deng Feng Project of First People’s Hospital of Foshan (2019A008).
- Organisation Unit
- School of Science and Engineering - Legacy; GeneCology Research Centre - Legacy; School of Science, Technology and Engineering; Centre for Bioinnovation
- Language
- English
- Record Identifier
- 991137306202621
- Output Type
- Journal article
Metrics
1 File views/ downloads
50 Record Views